TCGA-ZF-AA5P-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.22076216
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- TNFA_SIGNALING_VIA_NFKB+0.540
- MYOGENESIS+0.470
- ANGIOGENESIS+0.440
- COAGULATION+0.420
- IL6_JAK_STAT3_SIGNALING+0.420
- INFLAMMATORY_RESPONSE+0.420
- KRAS_SIGNALING_UP+0.350
- IL2_STAT5_SIGNALING+0.330
- UV_RESPONSE_DN+0.320
Top 10 suppressed
- E2F_TARGETS-0.580
- MYC_TARGETS_V1-0.560
- G2M_CHECKPOINT-0.510
- PROTEIN_SECRETION-0.460
- MYC_TARGETS_V2-0.390
- DNA_REPAIR-0.360
- OXIDATIVE_PHOSPHORYLATION-0.330
- MTORC1_SIGNALING-0.320
- MITOTIC_SPINDLE-0.300
- GLYCOLYSIS-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-K4-A83P-01A-11R-A352-07 | — | — | 0.942 |
| 2 | TCGA-98-A53D-01A-32R-A262-07 | — | cohortMD2 | 0.937 |
| 3 | C3L-00412 | — | cohortA1 | 0.920 |
| 4 | TCGA-CN-4728-01A-01R-1436-07 | — | — | 0.916 |
| 5 | DRR168569 | — | — | 0.910 |
| 6 | TCGA-XF-AAME-01A-12R-A42T-07 | — | — | 0.910 |
| 7 | TCGA-CN-5358-01A-01R-1514-07 | — | — | 0.907 |
| 8 | GSM5359443 | — | — | 0.907 |
| 9 | SRR12202494 | — | — | 0.905 |
| 10 | TCGA-LL-A440-01A-11R-A24H-07 | — | A | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.540 | Inavolisib | — uncovered |
| MYOGENESIS | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |